第十一批药品集采坚决“反内卷”，国家医保局：企业不得低于成本报价

Core Points - The National Healthcare Security Administration (NHSA) released the 11th batch of centralized drug procurement documents, emphasizing principles such as "stabilizing clinical needs, ensuring quality, preventing collusion, and countering excessive competition" [1][2] - The procurement aims to optimize the matching of clinical demand and supply by allowing medical institutions to report quantities based on both generic names and specific brands [1] - The procurement volume is set at 60% to 80% of the reported quantities, with the remaining portion left for medical institutions to choose brands independently [1] Group 1 - The procurement process incorporates feedback from drug regulatory and market supervision departments, raising quality control standards for bidding companies [2] - Measures against collusion and bid-rigging have been strengthened, with violators facing strict penalties under the procurement regulations [2] - The price control mechanism has been optimized, using the "50% of the average winning bid" as a new benchmark when the lowest bid is below this threshold [2] Group 2 - The procurement emphasizes transparency and fairness in market competition, requiring companies to submit bids that are not below their production costs [2] - Companies bidding below the benchmark price must provide a detailed explanation of their cost structure, addressing concerns about low-price bids [2] - Special attention is given to ensuring the supply of pediatric medications, with adjusted pricing rules for small specifications to encourage availability [1]